China Pneumonia Update
Macrolide-Resistant Mycoplasma pneumoniae in focus.
U.S. government agencies are fond of talking about “Pandemic Preparedness,” passing extravagant legislation such as the PREP ACT, and throwing hundreds of billions at the development of vaccines against viral respiratory illnesses—vaccines that are useless at best.
And yet, these agencies are, at the moment, strangely silent about a mysterious pneumonia that is affecting large numbers of children in two regions of northern China that are about 500 miles apart—Beijing and Liaoning Province. This situation reminds me of the conspicuous fact that the U.S. Consulate General office in Wuhan—which is presumably full of spooks—apparently reported NOTHING about the mysterious pneumonia that started circulating in that city in the autumn of 2019.
On Tuesday, November 21, ProMED—the largest publicly-available surveillance system conducting global reporting of infectious diseases outbreaks—published a report on these clusters of pneumonia cases in Beijing and Liaoning.
With the outbreak of pneumonia in China, children's hospitals in Beijing, Liaoning and other places were overwhelmed with sick children, and schools and classes were on the verge of suspension. Parents questioned whether the authorities were covering up the epidemic.
In the early morning, Beijing Children's Hospital was still overcrowded with parents and children whose children had pneumonia and came to seek treatment. Mr. [W], a Beijing citizen: "Many, many are hospitalized. They don't cough and have no symptoms. They just have a high temperature (fever) and many develop pulmonary nodules."
The situation in Liaoning Province is also serious. The lobby of Dalian Children's Hospital is full of sick children receiving intravenous drips. There are also queues of patients at the traditional Chinese medicine hospitals and the central hospitals. A staff member of Dalian Central Hospital said: "Patients have to wait in line for 2 hours, and we are all in the emergency department and there are no general outpatient clinics."
Some school classes have even been canceled completely. Not only are all students sick, but teachers are also infected with pneumonia. ...
ProMED was the first surveillance system that reported the mysterious pneumonia circulating in Wuhan. Chinese health agencies are claiming that the illness is NOT caused by a novel pathogen, but by a group of known pathogens such as mycoplasma pneumoniae, RSV, adenovirus and influenza.
Of these, mycoplasma pneumoniae—a common bacterial infection—has received special attention in China in recent years. As Bloomberg reported today:
China has the world’s highest incidence of mycoplasma pneumoniae that’s resistant to a class of antibiotic called macrolides. Up to 60% to 70% of adult cases and up to 80% of cases in kids don’t respond to Zithromax and similar drugs, Yin Yudong, an infectious diseases doctor at Beijing Chaoyang Hospital, the nation’s top respiratory disease center, told Beijing News earlier this month.
Another class of antibiotics called Fluoroquinolones seem to work when Macrolides don’t. This is consistent with a case study that Dr. McCullough identified yesterday—a man who recently became extremely ill with pneumonia after visiting northern China, but quickly responded to levofloxaxin, a fluoroquinolone antibiotic. There is some concern that levofloxaxin administered to small children could present a risk of joint damage, but this risk is manageable with proper pediatric dosing for a short duration.
Yesterday I found a host of academic medical literature, published by Chinese researchers since 2021, about virulent, Macrolide-Resistant Mycoplasma pneumoniae. Especially noteworthy is a 2021 paper titled Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors.
A fascinating feature of the mycoplasma bacteria is its ability to produce an exotoxin called Community-acquired respiratory distress syndrome toxin or CARDS TX. To quote from the above paper:
The discovery of CARDS TX of M. pneumoniae challenged the previously held belief that mycoplasmas are devoid of exotoxins. CARDS TX was originally a membrane-associated, surfactant protein A (SP-A)-binding, ADP-ribosylating, and vacuolating toxin identified by Kannan and Baseman when studying the pathogenic factors that may be responsible for respiratory epithelial cell damage by M. pneumoniae 
Upon reading this, I immediately wondered if the production of CARDS TX can be manipulated in a lab by means of Gain of Function.
The WHO has asked Chinese authorities to provide additional information about this pneumonia outbreak. So far, I’ve seen no advisories issued by the U.S. State Department or CDC.
We will be monitoring the situation in China closely, try to ascertain as quickly as possible what is causing the pneumonia.
In his position of Chief Scientific Officer for the Wellness Company, Dr. Peter McCullough is conducting investigative scholarship to ascertain what medications are the most safe and effective for conditions such as the pneumonia now circulating in northern China. Our ultimate objective is to ascertain if already available, FDA-approved medications could be useful in treating this pneumonia in the event it spreads to the United States.
Given the appalling performance of so many doctors during the COVID-19 pandemic, many of our readers may find themselves in search of a new doctor who has demonstrated greater discernment. Such readers may consider a membership with the Wellness Company, whose Virtual Care program offers prompt access to a trusted medical provider to treat your illnesses and obtain prescriptions.
The Wellness Company is also offering Home Medical Kits to treat a range of infections, including COVID-19, bronchitis, urinary tract infections, cellulitis, yeast infections, and tick bites. The Kit contains ivermectin, amoxicillin, a Z-pak, and other medications, as well as a guidebook and a doctor visit by telemedicine to aid in the proper use of these medications. Additional or different medications may be added to the Home Medical Kits when appropriate.